
Associated Press - August 26, 2009
J&J's Tibotec unit issued a letter to physicians about severe skin reactions and liver damage among patients taking the drug. The Food and Drug Administration has added information about the side effects to the drug's labeling.
The skin reactions included cases of Stevens-Johnson Syndrome, a life-threatening skin disorder that begins with fever, sore throat and fatigue. Some of the allergic reactions resulted in liver failure, according to the labeling.
The new label warns physicians to discontinue use of the drug if patients develop rash, fever, fatigue and other signs of an adverse reaction.
Intelence is a non-nucleoside reverse transcriptase inhibitor, or NNRTI, that blocks the enzyme HIV needs to multiply.
Tibotec Therapeutics is a division of Ortho Biotech Products LP, a Johnson & Johnson company based in Bridgewater, N.J.
090826
AP090825
Copyright © 2009 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .